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Abstract 
Background: Impaired glucose regulation represents an opportunity to prevent Type 2 diabetes 
mellitus. It is important to have a clear understanding of the prevalence of this condition in order to be 
able to plan interventions and health care provision. This paper presents a meta-analysis of literature 
assessing the prevalence of impaired glucose regulation in the general population of developed 
countries in Europe. 
Methods: Five electronic databases were systematically searched in March 2014 to identify 
English language articles with general population samples aged 18 and over from developed countries 
in Europe. Values for the measures of interest were combined using a random effects model and 
analysis of the effects of moderator variables was carried out.  
Results:  A total of 5594 abstracts were screened, with 46 studies included in the review. Overall 
prevalence of impaired glucose regulation was 22.3%. Mean prevalence of impaired glucose tolerance 
was 11.4% (10.1-12.8) and did not differ by gender. Sample age, diagnostic criteria and country were 
found to have a significant univariate effect on prevalence of impaired glucose tolerance but only 
diagnostic criteria remained significant in multivariate analysis. Mean prevalence of impaired fasting 
glucose was significantly higher in men at 10.1% (7.9-12.7) compared to 5.9% in women (4-8.7). The 
only moderator variable with a significant effect on impaired fasting glucose prevalence was country.  
Conclusions: This meta-analysis shows a moderate prevalence of impaired glucose regulation in 
developed Europe with over one in five people meeting the criteria for either impaired glucose 
tolerance, impaired fasting glucose, or both.  
Keywords: Prediabetic state; Prevalence; Europe; Meta-analysis. 
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Introduction 
People with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) have blood 
glucose levels that are higher than normal but do not meet the diagnostic criteria for Type 2 diabetes 
mellitus (Type 2 DM). These two states, known collectively as Impaired Glucose Regulation (IGR), 
confer an increased risk of developing type 2 DM [1]. IGT was first formally recognised in published 
diagnostic guidance for diabetes in 1979 [2] while IFG was not recognised until 1997 [3] with the 
precise glucose levels used to diagnose IFG and IGT depending upon the specific guidance used. In 
the most current guidance from ADA [4] and WHO [5], IGT is defined as an elevated two hour 
plasma glucose (2hPG) concentration after an oral glucose tolerance test (OGTT) of between 7.8 and 
11.1 mmol/l and a fasting plasma glucose (FPG) concentration of less than 7 mmol/l. The ADA define 
IFG as an FPG of between 5.6 and 6.9mmol/l and WHO define it as an FPG of between 6.1 to 6.9 
mmol/l and (if measured) a 2hPG in the normal range (less than 7.8mmol/l). 
Although people with IGR are at an increased risk of type 2 DM, research has shown that by making 
lifestyle changes they can prevent or delay progression to type 2 DM [1]. With prevalence of type 2 
DM increasing rapidly, a diagnosis of IGR represents an opportunity for intervention to reduce the 
burden of type 2 DM [6]. It is important to have a full and clear understanding of the prevalence of 
this condition in order to be able to plan such interventions and health care provision. Estimates of 
IGR prevalence vary greatly from study to study. A study of IGR prevalence in 13 population groups 
in 9 European countries reported estimates of IGR ranging from 3.2% to 64.2% [7]. It is likely that 
this variation in reported rates is due to a number of factors such as distribution of age and sex in the 
sample, differences in the data collection methodology and in the criteria used to classify IFG and 
IGT. In order to provide a clearer understanding of IGR prevalence and the factors affecting reported 
estimates, we carried out a meta-analysis of observational studies assessing the prevalence or 
incidence of IGR in the general population of adults in developed countries in Europe. We determined 
an overall prevalence estimate for IGR and examined moderator variables that potentially influenced 
this estimate. 
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Methods 
Literature search and study selection 
A meta-analysis of published studies reporting prevalence and incidence of IGR was undertaken in 
accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines 
for reviews [8]. All authors have previously conducted systematic reviews that have been published in 
peer reviewed journals. After consulting colleagues with expertise in meta-analysis and a librarian at 
the University of Stirling regarding the search strategy, a search was conducted in MEDLINE, 
EMBASE, CINAHL, Health Source and PsycInfo for articles published in English from January 1948 
to March 2014. The following combination of search terms were used with each database: (prevalence 
or incidence) and (impaired glucose tolerance or impaired fasting glucose or prediabetes or pre-
diabetes or impaired glucose regulation). Key authors and experts in the in the field were not 
contacted due to the time consuming nature of this process with no guarantee of obtaining relevant 
information.   
After removing duplicates, the title and abstract of each paper were screened by two authors (CE and 
JE or EF) against the following inclusion criteria:  
1) Population: general population, men or women, aged 18 and over, living in a developed 
country in Europe (as defined by the Financial Times Stock Exchange). 
2) Outcome measure: prevalence of IFG and/or IGT diagnosed using FPG and/or 2hPG in a way 
that is consistent with WHO criteria published from 1980 to 2006 or National Diabetes 
Group/ADA criteria from 1979 to 2011. 
3) Study design: observational study, published in English.  
All papers were screened by CE; JE and EF each screened half of the papers. In cases of disagreement 
between authors about the inclusion of a paper, the full text of the paper was accessed and consensus 
was reached through discussion. The review was limited to developed countries in Europe because of 
the wide differences in prevalence of type 2 DM and impaired glucose regulation between developed 
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and developing countries [9, 10]. This removed one potential source of heterogeneity in the review 
and also ensured that it is relevant for informing care and development of interventions in the context 
of developed health care systems. Studies were defined as having a sample drawn from the general 
population if it was drawn from a source that covered the majority of the population, such as census, 
other population register or general practice register (in countries where registration at general 
practice is near to universal). If this information was not reported, studies were only included if the 
paper explicitly stated that the sample was drawn from a general population. Studies that selected 
people who were at high risk of IGR (due to family history of type 2 DM, or lifestyle and medical 
factors), or who were recruited from hospital clinics or workplaces, were excluded. The full text of 
papers were retrieved for studies that were considered relevant, but also for those that contained 
insufficient information to allow judgement of relevance. Reference lists of included articles were 
reviewed to identify any additional relevant articles. 
Data extraction and coding 
Data were extracted and summarised from potentially relevant studies by one author (CE) using a 
standardised data extraction form based on the example provided by the Centre for Reviews and 
Dissemination [11]. Confidence intervals were calculated where possible for studies that did not 
report these for prevalence figures. Where there were multiple papers published that were based upon 
the same sample, only the paper reporting the most complete and definitive results was included. 
However, more than one paper from the same sample was included in the review if each paper 
reported on a unique aspect of the findings.   
The following information was extracted from each included study: first author, journal name and 
year of publication, country of study population, study period, study sample type, study design, age 
range, response rate, sample size, gender distribution in the sample (100% male, 100% female or 
mixed) and diagnostic criteria for IGT and/or IFG. The outcome measures extracted were number and 
proportion of sample with IGT and/or IFG, and number and proportion of sample with IGT and/or 
IFG by age and gender. The diagnostic criteria for IGT were split into four categories, with the widest 
criteria in Category 1 through to the narrowest in Category 4:  1) 2hPG 7.8-<11.1mmol/l (e.g. ADA 
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1997 [3]); 2) FPG <8.0mmol/l and 2hPG 8.0-<11.0mmol/l (e.g. WHO 1980 [12]); ]);  3) 
FPG<7.8mmol/l and 2h 7.8-<11.1mmol/l (WHO 1985 [13]) 4) FPG <7.0mmol/l and 2hPG 7.8-
<11.1mmol/l (e.g. WHO 2006 [5]). Similarly, diagnostic criteria for IFG were split into three 
categories, with the widest criteria in Category 1 through to the narrowest in Category 3: 1) FPG 5.6-
6.9mmol/l (e.g. ADA 2003 [14]); 2) FPG 6.1-6.9mmo/l (e.g. ADA 1997 [3]); 3) FPG 6.1-6.9 and 
2hPG <7.8mmo/l (WHO 1999 [15]) 
Where studies reported multiple prevalence estimates according to different diagnostic criteria, only 
one prevalence estimate was included in the meta-analysis to avoid dependency effects. For both IGT 
and IFG, the prevalence estimate generated by the most definitive criteria was selected, i.e. defined 
using both fasting and 2 hour samples. Otherwise, the criteria that was most commonly used in the 
papers included in the review was selected so that the estimate would be most comparable to other 
studies in the review.  For studies reporting multiple prevalence estimates by other factors, such as 
age or year, an average of the estimates was calculated and used in the analysis.    
Quality appraisal 
 
The quality of included studies was assessed using a checklist based upon the example published by 
the Joanna Briggs Institute [16] which was designed for assessment of quality in systematic reviews 
of prevalence and incidence. Quality assessment was completed for all included papers by one author 
(CE) and a list of all identified weaknesses was compiled.  The list was then discussed by all of the 
authors and the weaknesses were categorised as either major or minor. Major weaknesses were those 
that put the study at high risk of bias or made the risk of bias difficult to assess. They included not 
reporting participation rate, very low participation rate (<50%) or not reporting the source of the study 
sample (e.g. census, general practice register). Participation rates can be defined in many ways but for 
this review the participation rate (recoded during data extraction if necessary and possible) was the 
proportion of eligible people sampled who completed testing for IGT or IFG. Minor weaknesses were 
those that were less likely to put the study at risk of bias, and included low participation rate (50-
70%), not reporting differences between participants and non-participants, not reporting who carried 
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out blood samples, not reporting the proportions of men and women in the sample, and not reporting 
the details of fasting duration or what happened to non-fasters.  
Included studies were then given a quality rating as follows: 
 1: Only minor weaknesses, excluding a low participation rate. 
 2: Only minor weaknesses, including a low participation rate. 
3:  One major weakness.   
Data Analysis 
 
The meta-analysis was carried out using the Comprehensive Meta-Analysis software version 3.3.070 
(Biostat, Englewood, NJ). For each study, the proportion of people with IGR was transformed into a 
logit event rate effect size and the standard error associated with this was calculated [17]. The logits 
were retransformed to proportions after analysis to aid interpretation of the results. Combined effect 
sizes were calculated and analyses were carried out both including and excluding outlying logit event 
rates. No significant differences were found so outliers were retained in the analyses.  
Significance tests and moderator analysis were carried out using a random effects model. Fixed 
effects models make the assumption that the effect size observed in a study estimates the 
corresponding population effect with random error that comes only from the chance factors associated 
with subject level sampling error [17].  In contrast, random effects models allow for the possibility 
that there are also random difference between studies that are not only due to sampling error but as a 
result of some other factor such as variations in procedures, measures or settings. The choice of the 
random effects model to combine studies in this meta-analysis was based upon literature on IGR 
prevalence which suggests that the variability in reported prevalence for IGR may be the result of the 
use of different methodologies and criteria [7].  
The homogeneity of studies was evaluated using the Q test where the null hypothesis states that 
variability of the effect sizes is the result of sampling error only. If the assumption of homogeneity is 
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violated it is customary for sources of variation to be explored by studying moderator variables. Q and 
I2 statistics were also calculated to assess differences in combined effect sizes for sets of studies 
grouped according to moderator variables.  
Categorical moderator variables were analysed using an analysis of variance for meta-analysis. 
Differences between subgroups of these variables were explored using a test of interaction. The 
between study homogeneity statistic (QB) reflects the amount of heterogeneity that can be attributed to 
the moderator variable. The within study homogeneity statistic indicates the degree of heterogeneity 
that remains in the category in question (QW) and the I2 statistic shows the proportion of the variation 
that is due to heterogeneity rather than sampling error. For continuous variables, a simple weighted 
regression was used, where QR represents the proportion of variability associated with the regression 
model and QE indicates the variability unaccounted for by the model.  
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Results 
Description of Included Studies 
Figure 1 shows a PRISMA flow diagram of studies identified by the search. The search identified 
5,594 abstracts of which 148 were potentially relevant after title and abstract screening. The full text 
articles were retrieved and assessed against the inclusion criteria, resulting in 46 included studies 
reported in 53 papers (additional papers: [18-24]). These 46 studies included a total of 77,379 
participants. The characteristics of the studies included in the review are presented in Table 1 (online 
supplementary file). Of the 46 studies included, 13 assessed prevalence of IGT [25-37], 11 assessed 
the prevalence of IFG [38-48] and 22 reported the prevalence of both IFG and IGT [49-70]. In total, 
prevalence of IGT was reported in 35 different samples and IFG in 33 samples No studies were 
identified that assessed incidence of IGR. Of the 35 studies where IGT prevalence was reported, 
prevalence was reported separately for men and women in 19. For IFG, 25 out of 33 studies reported 
prevalence separately by sex. Studies were conducted across 11 of the 17 countries defined as 
developed European countries: Spain (n=11), UK (n=9), Finland (n=8), Sweden (n=5), Italy (n=4), 
France (n=3), Germany (n=2), Portugal (n=1), Denmark (n=1), the Netherlands (n=1) and Greece 
(n=1).   No additional papers were identified by manual searching of reference lists.   
Quality of Studies 
The quality category assigned to each study is reported in Table 1. Six studies were identified that had 
two major weaknesses [71-76]: all six had not reported from where participants were selected, and 
also had either a low or unspecified participation rate.  These studies were excluded from the review 
as this particular combination of problems made it difficult to assess the risk of bias in the study. 
Another study was excluded from the review as the reported prevalence estimates, sample size and the 
number with IGT reported in the paper were inconsistent with each other [77]. The majority of 
included studies were classed as either the higher (n=15) or middle quality category (n=16) and 
therefore had only minor weaknesses. The remaining studies fell in to the lower quality category 
(n=16) and in addition to any minor weaknesses also had one major weakness. The most common 
major weaknesses found in the lower quality studies were a very low participation rate (n=5) followed 
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by non-reporting of where participants were selected from (n=8) and non-reporting of participation 
rate (n=2). Of the weaknesses categorised as minor by the authors of this meta-analysis, the most 
common problems were non-reporting of who carried out blood glucose measurements (n=32), non-
reporting of checks on fasting status of participants (n=32); non-reporting of information on non-
responders (n=26) and low participation rate (n=18). Less common minor problems were non-
reporting of details about the duration of fasting prior to measuring blood glucose (n=8) and non-
reporting of the sex split of the sample (n=6).  
Analysis of Outliers  
In total four outliers were identified, three for IGT [31, 35, 36] and one for IFG [50].  The three 
outliers for IGT all reported prevalence of over 28% and the outlier for IFG reported prevalence in 
females of 17.6%. Sample age would appear to be the most obvious explanation for the high 
prevalence estimates in these studies, with three having samples aged 60 and older [31, 36, 50] and 
one with a sample aged 55 [35].   
Mean Prevalence of IGT  
The mean prevalence of IGT overall was 11.4% (95% CI: 10.1-12.8). The mean prevalence of IGT in 
men was 12.9% (10-16.4), 13.2% in women (10.5-16.5) and 9.9% (8.3-11.7) in mixed samples. There 
was no significant difference in prevalence of IGT between men and women (Q(1)=0.02; p=0.089). 
The analysis of homogeneity in the data with regards to sex showed variability within the studies 
assessing prevalence in men (Q(19)=500.73; p<0.001), those with women (Q(19)=670.22; p<0.001) and 
those with mixed samples (Q(12)=293.58; p<0.001). 
Analysis of Moderators for IGT 
As there was no significant difference in prevalence of IGT by sex, the analysis of prevalence by 
moderator variables is presented in overall terms. Table 2 shows the individual effects of different 
categorical moderator variables with the unit of analysis in all cases being the study. The effect of the 
continuous variable year is presented separately below. Sample age, diagnostic criteria and country 
the study was conducted in were found to have a significant effect on prevalence of IGT whereas the 
quality category of the study and year of data collection did not.  
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Sample Age 
The highest prevalence was found in samples aged 66 and over (25.1%; 17.8-34.1) followed by 
samples aged 30 to 65 (11.8%; 9.8-14.2) and the lowest prevalence was in samples aged 18 and over 
(9.4%; 7.1-12.4).  
Diagnostic Criteria 
Analysis of the effect of the four diagnostic categories on IGT prevalence found the highest 
prevalence estimate in studies using the second widest diagnostic criteria (19.7%; 13.9-27.2). 
Contrary to what would be expected, the lowest prevalence estimate of 7.4% (5.7-9.6) was found in 
studies using the widest category. However, this category contained only two studies so the results 
need to be interpreted with caution. The next lowest prevalence was found for studies using the 
second narrowest criteria (10.3%; 8.6-12.2). The widest category had a mean prevalence of 13% (9.2-
18.2), but again this category contained only two studies so results should be interpreted with caution.  
Country 
In the analysis by country, the highest prevalence was found in studies conducted in Finland (19.9%; 
14.8-26.2) and the lowest in Italy (6.9%; 5.4-8.7).  
Year 
 With regard to the year in which data collection was completed, the simple regression for meta-
analysis revealed no relationship between this variable and prevalence rates for IGT (QR(1)=2.8, 
R2=4%, p=0.0942). 
Multivariate analysis 
With the complexity of the univariate results and the fact that none of the moderator variables alone 
can explain a substantial part of the observed variability in prevalence of IGT, a weighted multiple 
regression was performed in order to explore which variables independently made the greatest 
contribution to the variability in prevalence of IGT. Variables that were significant in the univariate 
analyses (sample age, diagnostic criteria and country) were entered in to the model. These three 
variables accounted for 35% of total observed variability (QR(13)=39.88, p<0.001, see Table 3 for full 
results) but only diagnostic criteria remained statistically significant when the other two variables 
were held constant.  However, the residual model was also statistically significant (QE(17)=475.54; 
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p<0.001, I2=96.4%) meaning that there was still variability in the data that was not explained by the 
variables analysed.  
Mean Prevalence of IFG 
The mean overall prevalence of IFG was 8.4% (7.1-9.9). The mean prevalence of IFG in males was 
10.1% (7.9-12.7), 5.9% in females (4-8.7) and 8.1% (6.1-10.6) in mixed samples. The prevalence of 
IFG was significantly higher in men than women (Q(1)=5.28; p=0.022). The analysis of homogeneity 
in the data with regards to sex showed variability within the studies with men (Q(14)=495.35; 
p<0.001), those with women (Q(13)=747.51; p<0.001) and those with mixed samples (Q(17)=1179.74; 
p<0.001).  
Analysis of Moderators for IFG 
As significant differences in IFG prevalence existed between men and women, analyses were 
conducted and presented separately by gender. Table 4 shows the individual effects of different 
categorical moderator variables. The effect of the continuous variable year is presented separately 
below. The country in which the study was conducted had a significant effect on prevalence for both 
men and women. Sample age, quality category, diagnostic criteria and year had no effect on 
prevalence in either men or women.  
Country 
For both men and women prevalence was highest in Greece (men: 20.5%, 18.5-22.6; women 12%, 
10.5-13.7) and lowest in Germany (men: 4.2%, 3.1-5.7; women: 1.9%, 1.1-3.2). However, there was 
only one study conducted in each of these countries so results must be interpreted with caution.  
Year 
With regard to the year in which data collection was completed, the simple regression for meta-
analysis revealed no relationship between this variable and prevalence rates for IFG in men 
(QR(1)=0.75, R2=0%, p=0.385) or women (QR(1)=0.07, R2=0%, p=0.785). 
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Mean Prevalence of combined IGT and IFG 
The term ‘combined IGT and IFG’ is used to refer to individuals who meet the criteria for both IGT 
and IFG. The prevalence of combined IGT and IFG was reported in 11 studies included in the review. 
The mean overall prevalence of combined IGT and IFG was 2.5% (2-3.2). The mean prevalence in 
men was 2.7% (1.1-6.5), 1.3% in women (0.3-4.8) and 2.6% (2-3.3) in mixed samples. There was no 
significant difference in combined prevalence of combined IGT and IFG between men than women 
(Q(1)=0.85; p=0.356). The analysis of homogeneity in the data with regards to sex showed variability 
within the studies with men (Q(1)=8.78; p=0.003), those with women (Q(1)=7.09; p=0.008) and those 
with mixed samples (Q(8)=68.7; p<0.001). 
Analysis of Moderators for combined IGT and IFG 
As there was no significant difference in prevalence of combined IGT/IFG by sex, the analysis of 
prevalence by moderator variables is presented in overall terms. Table 5 shows the individual effects 
of different moderator variables with the unit of analysis in all cases being the study. All studies 
assessing combined IGT and IFG used the same diagnostic criteria so this moderator variable is not 
included in the analysis. Sample age and country in which the study was conducted were found to 
have a significant effect on prevalence of IGT whereas the quality category of the study did not.  
Sample Age 
The highest prevalence was found in samples aged 18 and over (3.5%; 2.5-4.7) and the lowest 
prevalence was in samples aged 30 to 65 (1.9%; 1.5-2.5).  
Country  
In the analysis by country, the highest prevalence was found in studies conducted in Spain (3.4%; 2.5-
4.7) and the lowest was in Germany (1.2%; 0.8-1.9). However, there was only one study conducted in 
Germany so results must be interpreted with caution. 
Year 
With regard to the year in which data collection was completed, the simple regression for meta-
analysis revealed no relationship between this variable and prevalence rates for combined IGT and 
IFG (QR(1)=0.1, R2=0%, p=0.751). 
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Mulivariate analysis 
A weighted multiple regression was performed in order to explore which variables made the greatest 
contribution to the variability in prevalence of combined IGT and IFG. Variables that were significant 
in the univariate analyses (sample age and country) were entered in to the model. These three 
variables accounted for 47% of total observed variability (QR(7)=14.92, p=0.037, see Table 6 in online 
supplementary material for full results) but neither variable accounted for a significant amount of 
variance alone when the other variable was held constant.  However, the residual model was also 
statistically significant (QE(3)=15.46; p<0.001) meaning that there was still variability in the data that 
was not explained by the variables analysed. 
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Discussion 
This meta-analysis of 77,379 participants in 46 studies reported mean prevalence estimates of 11.4% 
for IGT, 8.4% for IFG and 2.5% for combined IGT and IFG. This suggests that the overall prevalence 
of IGR could be as high as 22.3%. No differences were found for prevalence of IGT or combined IGT 
and IFG by gender, but IFG estimates were found to be significantly higher in men than women. An 
increase in prevalence of IGT was found with increasing sample age. Diagnostic criteria and country 
were also found to have an effect on IGT prevalence.  The only variables that had a significant effect 
on IFG prevalence was the country in which the study was conducted. There were no clear trends in 
either IGT or IFG prevalence over time. 
The study methods were systematic and robust. We used independent reviewers to screen all of the 
titles and abstracts identified by the search for inclusion in the review. All decisions on the inclusion 
of papers were discussed and agreed upon by all three authors. A thorough quality assessment was 
conducted for all studies considered for inclusion using a template designed for observational 
epidemiology studies and the majority of studies included were of high quality. The methodology had 
only minor limitations: only papers published in the English language were included, experts in the 
field were not contacted, grey literature was not identified and data extraction was only carried out by 
one author.  
The quality assessment ensured that the majority of studies included in the review had relatively good 
participation rates and recruited participants from sources that have coverage of the majority of the 
population (e.g. census) using appropriate methods (e.g. random sample or whole population). This 
allows us to be reasonably confident that the included studies used samples that were representative of 
the general population. Indeed, quality category of the study was not found to have any significant 
effect on prevalence of IGR. Although participation rates were generally good for the majority of 
included studies, around one third of studies had participation rates that would be classified as average 
at between 50 and 70%, and one tenth of studies had very low participation rates of less than 50%. 
Non-reporting of various methodological details was a common problem which made it difficult to 
assess fully the quality of some studies.  However, the impact of this problem on the quality of the 
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review was minimised by the decision to exclude any studies that had more than one weakness 
defined by the authors as major. Collating data on IGT and IFG prevalence was also made difficult by 
heterogeneity in approaches to sampling, methods used to collect blood samples and the criteria used 
to define IFG and IGT. This heterogeneity may have accounted for some of the inconsistencies in 
findings.  
It is generally accepted that around 15% of adults in developed countries have some type of IGR, 
even though empirical estimates of prevalence vary widely [78]. This figure of 15% is based upon 
WHO criteria and comes from studies conducted in Europe, Asia and the United States, whereas our 
estimates are based on both WHO and recent ADA criteria which have a wider range of values for the 
diagnosis of IFG. Consistent with other research in Europe and the United States, we found that 
prevalence of IGR increased when wider criteria were used, although these findings were not 
statistically significant for IFG [16]. It is possible that our inclusion of studies using the new ADA 
criteria may have inflated the IGR estimate. However, the impact is unlikely to be large as the 
majority of included studies are based upon older, narrower criteria for IGR. Given the differences 
between our review and the studies upon which the 15% estimate was based, these estimates therefore 
accord well with each other.  
The trends found in this review of higher prevalence of IFG in men compared to women, higher 
prevalence of IGT but not IFG with increasing age and the higher prevalence of IGT compared to IFG 
are all consistent with the findings of the DECODE study in Europe and the DECODA study in Asia 
that explored these factors in 10 and 13 different samples respectively [7, 79-81]. However, we found 
no difference in IGT prevalence between men and women, whereas the DECODE and DECODA 
studies reported higher IGT prevalence in men compared to women; although it has  been noted that 
these sex differences were only significant in specific age groups and were less robust than those 
found for IFG.  
With IGR existing on a continuum with type 2 DM and sharing the same risk factors, we would 
expect to see increases in IGR over time mirroring those seen for type 2 diabetes [82]. One study 
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included in this paper that assessed four different samples recruited in the same way at four time 
points did find significant increases in both IGT and IFG between 1990 and 2004 [55]. However, the 
various factors identified by this review that influence IGR prevalence, such as age, gender and 
diagnostic criteria, and the differences in methodologies found across included studies, may have 
masked any possible temporal trends.  
In summary, this is the first meta-analysis to bring together all the relevant evidence relating to IGR 
prevalence in Europe and to make sense of disparate findings. In the general population of developed 
Europe, around 1 in 5 people meet the criteria for either impaired glucose tolerance, impaired fasting 
glucose, or both. These figures provide a basis for the planning of interventions and health care 
provision for the prevention of type 2 DM. We now recommend that similar meta-analyses be 
conducted in other populations for comparison, for example those from developing countries, and 
from North America and Asia.  
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Key Points 
 This meta-analysis is the first to summarise the disparate findings on prevalence of impaired 
glucose regulation in Europe.  
 A clear understanding of the prevalence of this condition is necessary for planning of health 
care provision. 
 This meta-analysis found that impaired glucose regulation is common in developed Europe 
with around 1 in 5 people meeting the criteria for IFG, IGT or both. 
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Tables 
Table 2 Mean prevalence of IGT by several moderator variables  
Variable k n Prevalence 95% CI QB (df) QW (df) I2 (%) 
Age 
18 and over 
 
8 
 
15,048 
 
9.4 
 
7.1-12.4 19.15 (2)* 
 
 
198.58 (7)* 
 
96.5 
30-65 23 45,828 11.8 9.8-14.2 1077.06 (22)* 98 
66+ 4 2,941 25.1 17.8-34.1 72.97 (3)* 95.9 
Diagnostic Criteria  
1. 2hPG 7.8-<11.1mmol/l 
 
2 
 
2,951 
 
7.4 
 
5.7-9.6 
 
19.9 (3)* 
 
3.86 (1)* 
 
74.1 
2. FPG <8.0mmol/l and 
2hPG 8.0-<11.0mmol/l 
8 10,047 19.7 13.9-27.2  361.41 (7)* 98.1 
3. FPG<7.8mmol/l and 2h 
7.8-<11.1mmol/l 
19 43,722 10.3 8.6-12.2  704.38 (18)* 97.4 
4. FPG <7.0mmol/l and 
2hPG 7.8-<11.1mmol/l 
2 3,678 13.9 7.6-24.2  49.83 (1)* 98 
Quality Category        
1 – Higher 13 21,651 12.8 10.3-15.7 0.59 (2) 338.8 (12)* 96.5 
2 12 25,686 11.5 9.3-14  370.82 (11)* 97 
3 – Lower 10 16,480 12.8 8-20  992.21 (9)* 99.1 
Country        
Denmark 1 6,784 12 11.2-12.8 43.46 (8)* 0.00 (0) 0.0 
25 
 
Finland 8 12,007 19.9 14.8-26.2  348.05 (7)* 98 
Germany 2 3,006 10.4 3.9-24.7  72.45 (1)* 98.6 
Italy 3 3,870 6.9 5.4-8.7  7.9 (2)* 74.7 
Netherlands 1 2,378 10.3 9.1-11.6  0.00 (0) 0.0 
Portugal 1 5,167 12.6 11.7-13.5  0.00 (0) 0.0 
Spain 7 11,817 9.5 7.0-12.7  151.38 (6)* 96 
Sweden 5 9,849 14 8.1-23  329.68 (4)* 98.8 
UK 7 9,659 11.1 8.6-14.3  79.9 (6)* 92.5 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity statistic; QW: 
within study homogeneity statistic; I2 proportion of variability within categories due to heterogeneity 
rather than sampling error.  
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Table 3 Weighted multiple regression for IGT prevalence  
  95% CI Q(B) (df) 
Age    
18 + - - 2.25 (2) 
30-65 0.25 -0.28- 1.01  
66+ 0.72 -0.29- 1.72  
Diagnostic Criteria    
1) 2hPG 7.8-<11.1mmol/l 0.49 -1.05-2.02 10.41 (3)* 
2) FPG <8.0mmol/l and 2hPG 8.0-<11.0mmol/l 0.72 -0.29-1.72  
3) FPG<7.8mmol/l and 2hPG 7.8-<11.1mmol/l 0.09 -0.94-1.12  
4) FPG <7.0mmol/l and 2hPG 7.8-<11.1mmol/ - -  
Country    
Denmark 0.81 -0.42-2.05 7.44 (8) 
Finland 0.96^ -0.04-1.96  
Germany 0.65 -0.43-1.74  
Italy  - -  
Netherlands 0.73 -0.88-2.34  
Portugal 1.12 -0.33-2.57  
Spain 0.53 -0.61-1.68  
Sweden 0.74 -0.25-1.74  
27 
 
UK 0.38 -0.62-1.38  
* p<0.05; ^ marginally significant p=0.0588; p QB: between study homogeneity statistic;  
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Table 4 Mean prevalence of IFG in men and women by several moderator variables 
Variable k N Prevalence 95% CI QB (df) QW (df) I2 (%) 
 Men  
Age        
18 and over  6 5,548 10 6.6-14.8 0.13 (2) 121.7 (5)* 95.9 
30-65  7 8,480 10.6 8.7-12.9  55.67 (6)* 89.2 
66+  2 7,385 8.9 2-3.2  298.06 (1)* 99.7 
Diagnostic Criteria        
1) FPG 5.6-6.9mmol/l 2 2,298 13 4.8-30.6 0.37(2) 56.13 (1)* 98.2 
2) FPG 6.1-6.9mmo/l  8 14,668 10.7 7.7-14.8   306.42 (7)* 97.7 
3) FPG 6.1-6.9 and 2hPG <7.8mmo/l  4 3,999 9.7 6.4-14.3  52.87 (3)* 94.3 
Quality Category        
1 – Higher  6 6,685 10.6 8.7-12.8 0.09 (2) 30.24 (5)* 83.5 
2  5 8,523 10.9 7.5-15.4  129.52 (4)* 96.9 
3 – Lower  4 6,205 9.4 3.7-21.8  298.73 (3)* 99 
Country        
Finland 2 2,320 11.6 8.6-15.3 
136.74 
(8)* 
6.39 (1)* 84.4 
France  3 6,177 7.5 3.6-14.9  111.53 (2)* 98.2 
Germany  1 896 4.2 3.1-5.7  0.00 (0) 0.0 
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Greece  
1 1,514 20.5 
18.5-
22.6 
 0.00 (0) 0.0 
Italy  
1 2,240 12.2 
10.9-
13.6 
 0.00 (0) 0.0 
Netherlands  
1 2,378 12 
10.8-
13.4 
 0.00 (0) 0.0 
Spain  2 752 6.1 1.9-18.4  15.4 (1)* 93.5 
Sweden  1 359 10.6 7.8-14.2  0.00 (0) 0.0 
UK  3 4,777 14.4 11-18.8  14.64 (2)* 86.3 
Variable k n Prevalence  QB (df) QW (df)  
 Women  
Age        
18 and over  6 6,685 6.5 4.4-9.7 0.96 (2) 91.2 (5)* 94.5 
30-65  6 6,169 5.2 3.9-6.8  31.32 (5)* 84 
66+  2 9,287 7.3 1.1-35.9  477.71 (1)* 99.8 
Diagnostic Criteria         
1) FPG 5.6-6.9mmol/l  7 14,610 7.2 3.9-13 1.27 (2) 549.58 (6)* 98.9 
2) FPG 6.1-6.9mmo/l  2 2,846 6.5 1.8-20.8  62.61 (1)* 98.4 
3) FPG 6.1-6.9 and 2hPG <7.8mmo/l  4 4,103 4.7 3.0-7.4  30.93 (3)* 90.3 
Quality Category        
30 
 
1 – Higher  5 4,977 5.9 3.9-9.1 0.06 (2) 47.09 (4)* 91.5 
2  5 8,298 6.3 3.0-12.7  287.22 (4)* 98.6 
3 – Lower  4 8,866 5.5 2.3-12.4  206.1 (3)* 98.5 
Country        
Finland  
2 2,595 5.1 4.3-6 
119.82 
(7)* 
0.12 (1) 0.0 
France  3 8,647 3.8 2.4-5.9  29.57 (2)* 93.2 
Germany  1 757 1.9 1.1-3.2  0.00 (0) 0.0 
Greece   
1 1,528 12 
10.5-
13.7 
 0.00 (0) 0.0 
Italy  1 2,497 9.9 8.8-11.1  0.00 (0) 0.0 
Spain  2 967 4.7 1.9-11.3  9.46 (1)* 89.4 
Sweden  1 382 6.3 4.3-9.2  0.00 (0) 0.0 
UK 3 4,771 10.6 5.6-19.2  56.12 (2)* 96.4 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity statistic; QW: 
within study homogeneity statistic; I2 proportion of variability within categories due to heterogeneity 
rather than sampling error. 
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Table 5 Mean prevalence of combined IGT and IFG by several moderator variables 
Variable k n Prevalence 95% CI QB (df) QW (df) I2 (%) 
Age 
18 and over  
 
4 
 
9,959 
 
3.5 
 
2.5-4.7  
7.94 (2)* 
 
21.53 (3)* 
 
86.1 
30-65  6  14,605 1.9 1.5-2.5 24.88 (5)* 79.9 
66+ 1 499 2.7 1.6-4.6 0.00 (0) 0.0 
Quality Category        
1 – Higher  2 6,077 3.2 1.7-6 1.63 (2) 12.5 (1)* 92 
2  3 5,908 1.8 1-3.4  21.95 (2)* 90.9 
3 – Lower  6 13,080 2.6 1.9-3.6  42.26 (5)* 88.2 
Country        
Finland  2 3,217 1.9 1.1-3.4 15.12 (5)* 3.56 (1)* 71.9 
Germany  1 1,653 1.2 0.8-1.9  0.00 (0) 0.0 
Italy  1 919 2.1 1.3-3.3  0.00 (0) 0.0 
Portugal  1 5,167 2.4 2-2.9  0.00 (0) 0.0 
Spain  4 7,882 3.4 2.5-4.7  19.79 (3)* 84.8 
UK 2 6,225 2.4 1.2-4.5  14.2 (1)* 93 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity statistic; QW: 
within study homogeneity statistic; I2 proportion of variability within categories due to heterogeneity 
rather than sampling error. 
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